Cell therapy company Bone Therapeutics has announced it is shifting its R&D activities towards its most advanced clinical asset, the allogenic cell therapy platform, ALLOB. The platform ALLOB is an off-the-shelf allogenic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. […]
